Vol 20. N°4. 2019  |  Diciembre de 2019


REVISIÓN - FÁRMACOS Y NUTRICIÓN


REVISIÓN DE LOS FÁRMACOS MÁS USADOS EN OBESIDAD A NIVEL MUNDIAL


Autores: RAÚL SANDRO MURRAY, MARTA A. SÁNCHEZ, CESAR CASÁVOLA, PABLO LÓPEZ SCHIMPF, ANA L. CASCÚ, FRANCISCO A. D'ONOFRIO


RESUMEN

La obesidad es una enfermedad crónica multifactorial que favorece la aparición de enfermedades asociadas (diabetes tipo 2, hipertensión arterial, dislipidemia, enfermedades cardiovasculares, algunos tipos de cánceres), altera la calidad de vida en general (emocional, social, económica, etc.) y produce una mayor mortalidad global. La obesidad (y sus complicaciones) es uno de los tres principales factores, junto con el tabaquismo y el alcoholismo que generan gran impacto económico. En Argentina, desde hace mucho tiempo, los fármacos para el tratamiento de la obesidad lo emplea un gran número de médicos que, en muchas ocasiones, no tiene la capacitación adecuada en la utilización y prescripción de estos medicamentos, lo cual genera un uso imprudente, abusivo y riesgoso para la salud. En Argentina existe la Guía de Práctica Clínica en Obesidad, desarrollada por el Ministerio de Salud de la Nación. El Grupo de Trabajo Fármacos y Nutrición de la Sociedad Argentina de Nutrición (SAN) realizó una revisión de las principales drogas y combinaciones existentes a nivel mundial para que los profesionales de la salud cuenten con una referencia científca actualizada al momento de la elección criteriosa de las mismas.

PALABRAS CLAVE: obesidad; fármacos; terapéutica.

REFERENCIAS:
1. Rehar R. Anorexigens: indications and interactions. Rev Chil Neuro Psiquiatr 2002; Vol 40, Nº 2.
2. Galicia M, Simal-Antón A. Tratamiento farmacológico de la obesidad. Sistema Nacional de Salud (Madrid) 2002; Vol. 26, Nº 5. Disponible en: http://www.msc.es/farmacia/infmedic.
3. Bolaños R, Méndez R. Consumo de mazindol en Argentina. Período 2006-2009. Ministerio de Salud (ANMAT). República Argentina.
4. Morín R, Lonngi G. Farmacoterapia de la obesidad. 2º Edi-ción. México 2012.
5. Suplici H, Boguszewski CL, dos Santos CM, et al. A compara-tive study of five centrally acting drugs on the pharmacologi-cal treatment of obesity. Journal Int J Obes (Lond); 2014 Aug; 38(8): 1097-103.
6. Severinsen K, Kolds H, Thorup KA, et al. A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. Mol Pharmacol 2014 Feb; 85(2):208-17.
7. Severinsen K, Koldsø H, Thorup KA, et al. Binding of ma-zindol and analogs to the human serotonin and dopamine transporters. Mol Pharmacol 2014 Feb; 85(2):208-17.
8. Mancini MC, Halpern A. Pharmacological treatment of obe-sity. Arq Bras Endocrinol Metabol 2006 Apr; 50(2):377-89.
9. Eficacia y regulación del mazindol. ANMAT. Disponible en: www.anmat.gov.ar/ets./Mazindol vpo3-9 (RL2)pdf.
10. http://www.anmat.gov.ar/webanmat/Legislacion/Medica-mentos/Disposicion_ANMAT_1031-1986.pdf.
11. Sakane N. Pharmacology in health foods: merits and deme-rits of food with health claims for the prevention of metabo-lic syndrome. J Pharmacol Sci 2011; 115(4):476-80.
12. Carvalho DF, Cercato C, Almeida MQ, Mancini MC, Halpern A. Therapeutical approach of obesity in Prader-Willi Syndro-me. Arq Bras Endocrinol Metabol 2007 Aug; 51(6):913-9
13. Scacchi J F, D ́Onofrio FA, et al. Ensayo clínico con mazindol, como coadyuvante en tratamiento de la obesidad en Tucu-mán, Argentina. Rev Mexicana de Cirugía del Aparato Diges-tivo 2017; Vol. 6 Nº 2: 48-54.
14. Montani D, Seferian A, Savale L, Simonneau G, Humbert M. Drug-induced pulmonary arterial hypertension: a recent out-break. Eur Respir Rev 2013 Sep; 22(129):244-50.
15. Morin ZR, et al. Anfepramona de liberación lenta como trata-miento de obesidad. Rev Mex Cardiol 2007;18(1): 9-16.
16. Allen GS. A double blind clinical trial of diethylpropion, ma-zindol and placebo in the treatment of the exogenous obesi-ty. Therapeutic Research 1977; Vol 22. Nº 5.
17. Fernández-Pellicer FJ. Adiposis dolorosa o enfermedad de Dercum. Semergen 2000; 26: 552-553.
18. Garin-Alegre M. Enfermedad de Madelung. Semergen 2012; 38(4):211-213.
19. Pelissier-Alicot AL, Piercecchi-Marti MD, Bartoli C, Kuhlmann E, Coiffait PE, Sanvoisin A, et al. Abusive prescription of psychostimulants: a study of two cases. J Forensic Sci 2006; 51(2):407-10. Disponible en: http://dx.doi.org/10.1111/j.1556-4029.2006.00078.
20. Verduzco FW. Fenproporex en el tratamiento de la obesidad y la hiperfagia por estrés. Revista Latinoamericana de Psi-quiatría 2012; Vol 11, Nº 2.
21. Rothman RB, Baumann MH. Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am J Ther 2009; 16:354-364.
22. Pasquali R, Casimitri F, Melchionda N, et al. Effects of chronic administration of ephedrine during very-low calorie diets on energy expenditure, protein metabolism and hormone levels in obese subjects. Clin Sci 1992; 82:85-92.
23. Lorello C, Goldfield GS, Doucer E. Methylphenidate hydro-chloride increases energy expenditure in healthy adults. Obe-sity 2008; 16:470-472.
24. Jones JR, Caul WF, Hill JO. The effects of amphetamine on body weight and energy expenditure. Physiol Behav 1992; 51:607-611.
25. Jaworska I, Budziszewska B, Lason W. The effect of repeated amphetamine administration on the proopiomelanocortin mRNA level in the rat pituitary. Drug Alcohol Depend 1994; 36:123-127.
26. Menyhert J, Wirtmann G, Lechan RM, et al. Cocaine and amphetamine-regulated transcript (CART) is colocalized with the orexigenic neuropeptide Y and agouti-related protein and absent from the anorexigenic alpha-melanocyte-stimula-ting hormone neurons in the infundibular nucleus of the hu-man hypothalamus. Endocrinology 2007; 148:4276-4281.
27. Gustafson A, King C, Rey JA. Lorcaserin (Belviq). A selective serotonin 5-HT2C agonist in the treatment of obesity. P T. 2013 Sep; 38(9): 525-530, 534.
28. Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR; APD356-004 Study Group. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 2009 Mar; 17(3):494-503.
29. Martin CK, Redman LM, Zhang J, Sanchez M, Ander CM, Smith SR, Ravussin E. Lorcaserin, a 5-HT(2C) receptor ago-nist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab 2011 Mar; 96(3):837-45. doi: 10.1210/jc.2010-1848. Epub 2010 Dec.
30. Nigro SC, Luon D, Baker WL. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity. Curr Med Res Opin 2013 Jul; 29(7):839-48.
31. Hess R, Cross LB. The safety and efficacy of lorcase-rin in the management of obesity. Postgrad Med. 2013 Nov;125(6):62-72.32. Lam DD, Przydzial MJ, Ridley SH, Yeo GS, Rochford JJ, O'Rahilly S, Heisler LK. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melano-cortin 4 receptors. Endocrinology 2008 Mar; 149(3):1323-8 Epub 2007 Nov 26.
33. Heisler LK, Jobst EE, Sutton GM, et al. Serotonin reciproca-lly regulates melanocortin neurons to modulate food intake. Neuron 2006; 51:239-249.
34. Usmani KA, Chen WG, Sadeque AJ. Identification of human cytochrome P450 and flavin-containing monooxygenase en-zymes involved in the metabolism of lorcaserin, a novel se-lective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos J 2012; 40:761-771.
35. Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev 2013 May; 14(5):383-92.
36. Taylor JR, Dietrich E, Powell J. Lorcaserin for weight manage-ment. Postgrad Med. 2013 Nov; 125(6):62-72.
37. Smith SR, Weissman NJ, Anderson CM, Sánchez M, Chuang E, Stubbe S, Bays H, Shanahan WR. Behavioral modification and lorcaserin for overweight and obesity management (BLOOM) Study Group Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010 Jul 15; 363(3):245-56.
38. Fidler MC, Sánchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, Anderson CM; BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin En-docrinol Metab 2011 Oct; 96(10):3067-77.
39. Hurren KM, Berlie HD. Lorcaserin: an investigational seroto-nin 2C agonist for weight loss. Am J Health Syst Pharm 2011 Nov 1; 68(21):2029-37.
40. Citrome L. Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out. Int J Clin Pract Dec 2014; 68, 12:1401-1405.
41. Weight loss medications approved by the FDA for long-term treatment of obesity. AACE 2016. Disponible en: http://obe-sity.aace.com/files/obesity/presentations/Sect3.3.WeightLossMedications.082516.pdf.
42. Hoy SM. Lorcaserin: a review of its use in chronic weight ma-nagement. Drugs 2013 Apr; 73(5):463-73.
43. Smith SR, Weisserman NJ, Anderson CM, et al. Multicenter, placebo controler trial of lorcaserin for weight management. N Engl J Med 2010; 363:245-256.
44. O'Neil PM, Smith SR, Weisserman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM Study. Obesity 2012; 20: 1426-1436.
45. Pi-Sunyer X. Avances en el tratamiento de la diabetes me-llitus tipo 2 y la enfermedad cardiovascular. Rev Esp Cardiol Supl 2008; 8(C):62-72.
46. Hernández-Rodríguez J, Licea-Pui ME, Castelo-Elías LC. Re-visión bibliográfica. Medicamentos que favorecen la pérdida de peso y el control metabólico en las personas obesas con diabetes tipo 2. Rev Cubana Endocrinol 2013; Vol 24 Nº 3.
47. Subash C, Sivaraman T, Barber M, O'Hare P, Harpal SR. Glu-cagon-like peptide-1 based therapies: effects beyond blood glucose control. The British Journal of Diabetes & Vascular Disease, October/December 2013; Vol 13, 5-6: 229-237.
48. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007 May; 132(6):2131-57.
49. Drucker DJ. The biology of incretin hormones. Cell Metabolic 2006 Mar; 3(3):153-65.
50. Knop FK, Holst JJ, Vilsbøll T. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility. Drugs 2008 Jul;11(7): 497-501.
51. Knop FK, Vilsbøll T, Holst JJ. Incretin-based therapy of type 2 diabetes mellitus. Curr Protein Pept Sci 2009 Feb; 10(1):46-55.
52. Tella SH, Rendell MS. Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Ther Adv Endocrinol Metab 2015 Jun; 6(3):109-34.
53. Sun F, Chai S, Li L, Yu K, Yang Z, Wu S, Zhang Y, Ji L, Zhan S. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis. J Diabetes Res 2015; 2015:157201.
54. Bashier AM, Hussain AA, Abdelgadir EI, Eltinay AT, Thadani P, Abdalla ME, Abusnana S, AlAwadi FF. Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial. J Diabetes Metab Disord 2015 May 30; 14:48.
55. Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Ji L, Zhan S. Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and net-work meta-analysis. Endocrine 2015 Apr; 48 (3):794-803.
56. Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.Diabetes Obes Metab 2013 Aug; 15(8):737-49.
57. Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, Tankova T, Mitha I, Matthews DR. Long-term effica-cy and safety comparison of liraglutide, glimepiride and pla-cebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab 2013 Mar; 15(3):204-12.
58. Iltz JL, Baker DE, Setter SM, Keith Campbell R. Exenatide: an incretin mimetic for the treatment of type 2 diabetes melli-tus. Clin Ther 2006 May; 28(5):65265.
59. Meier JJ. Agonistas del receptor GLP-1: el objetivo es con-trolar el riesgo vascular global en el tratamiento de la diabetes. Disponible en: https://img.medscape.com/arti-cle/823/771/823771_Span_Reprint.pdf
60. Masmiquel L. Efectos cardiovasculares y seguridad de los fár-macos hipoglucemiantes: situación actual. Elsevier 2014; Vol 40, Nº 2: 80-88.
61. VilsbØll T, Christensen M, Gluud L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic re-view and meta-analyses of randomised controlled trials. BMJ 2012 Jan 10; 344:d7771.
62. Crane J, McGowan B. The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. Ther Adv Chronic Dis 2016 Mar; 7(2):92-107.
63. Kurasaki K, Kigawa I, Sohara E, Hamano K. Effects of com-bination therapy with liraglutide and insulin glargine as the initial treatment for hyperglycemic patients with type 2 dia-betes: an observational study. International Journal of Diabe-tes & Clinical Diagnosis Dec 15, 2016; 3:121.
64. Seino Y, Kaneko S, Fukuda S, Osonoi T, Shiraiwa T, Nishijima K, Bosch-Traberg H, Kaku K. Combination therapy with lira-glutide and insulin in Japanese patients with type 2 diabetes: a 36-week, randomized, double-blind, parallel-group trial. J Diabetes Investig 2016 Jul; 7(4):565-73.
65. Vora J. Combining incretin-based therapies with insulin rea-lizing the potential in type 2 diabetes. Diabetes Care 2013 December; 36 (Supplement 2): S226-S232.
66. Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, Pedersen-Bjergaard U, Jensen T, Jensen AK, Holst JJ, Tarnow L, Knop FK, Madsbad S, Andersen HU. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabe-tes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endo-crinol 2016 Mar; 4(3):221-232.
67. Comisión de Obesidad: Introducción, Epidemiología. Avan-ces en Fisiopatología. Revista Argentina de Cardiología 2001; Vol 69, Suplemento 1.
68. Ballinger A. Orlistat in the treatment of obesity. Expert Opin Pharmacother 2000 May; 1(4):841-7.
69. Leung WY, Thomas GN, Chan JC, Tomlinson B. Weight ma-nagement and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther 2003 Jan; 25(1):58-80. Review.
70. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat associated adverse effects and drug interactions: a critical review. Drug Saf 2008; 31(1):53-65. Pub Med.
71. Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovas-cular risk factors after 2 years treatment with orlistat for obe-sity. European Orlistat Obesity Study Groobes Res 2000 Jan; 8(1):49-61.
72. Siebenhofer A, Jeitler K, Horvath K, Berghold A, Posch N, Meschik J, Semlitsch T. Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst Rev 2016 Mar 2; 3:Cd007654.
73. Siebenhofer A, Jeitler K, Horvath K, Berghold A, Siering U, Semlitsch T. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database Syst Rev. 2013 Mar 28; 3:Cd007654.
74. Johansson K, Sundström J, Neovius K, Rössner S, Neovius M. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. Obes Rev 2010 Nov; 11(11):777-91.
75. Pagotto U, Vanuzzo D, Vicennati V, Pasquali R. Pharmacolo-gical therapy of obesity. G Ital Cardiol (Rome). 2008 Apr; 9(4 Suppl 1):83S-93S.
76. Viner RM, Hsia Y, Tomsic T, Wong IC. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic re-view and meta-analysis. Obes Rev 2010 Aug; 11(8):593-602.
77. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. Jama 2014 Jan 1; 311(1):74-86.
78. Zhou YH, Ma XQ, Wu C, Lu J, Zhang SA, Guo J, Wu SQ, Ye XF, Xu JF, He J. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of rando-mized controlled trials. Plos One 2012; 7(6):E39062.
79. Hong Jl, Meier CR, Sandler RS, Jick SS, Stürmer T. Risk of colorectal cancer after initiation of orlistat: matched cohort study. BMJ 2013 Aug 27; 347:F5039.
80. Charakida M, Finer N. Drug treatment of obesity in car-diovascular disease. Am J Cardiovasc Drugs 2012 Apr 1; 12(2):93-104.
81. Londoño-Lemos ME. Tratamiento farmacológico contra la obesidad. Rev Colomb Cienc Quim Farm 2012; Vol 41, Nº 2: 217-261.
82. Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacothera-pies for obesity: past, current, and future therapies. J Obes 2011; 2011:179674.
83. Naltrexone hydrochloride. C20H24ClNO4. PubChem. Dis-ponible en: https://pubchem.ncbi.nlm.nih.gov/.../Naltrexo-ne_hydrochlorid.
84. Plodkowski RA, McGarvey ME, Reisinger-Kindle K, Kramer B, Nelson E, Lee J, Nguyen QT. Obesity management: clinical review and update of the pharmacologic treatment options. Journal List Fed Practv 2016; 33(1).
85. Bupropion hydrochloride. C13H19Cl2NO. PubChem. Dispo-nible en: https://pubchem.ncbi.nlm.nih.gov/.../Bupropion_hydrochloride.
86. Vega-Romero F, Sánchez- Calabuig M, Zaragozá- Harnáez F. Actualización en el tratamiento farmacológico de la obe-sidad. Revista de la Facultad de Ciencias de la Salud 2013; Vol. 8.
87. Valenzuela AM. CONTRAVE: la nueva esperanza farmaco-lógica para la obesidad. Revista de la Sociedad Chilena de Obesidad 2010.88. Plodkowski RA, Nguyen Q, Sundaram U, Nguyen L, Chau DL, St Jeor S. Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert Opin Pharmacother 2009; 10: 1069-1081.
89. Álvarez V. Tratamiento farmacológico de la obesidad. Revista Médica, Clínica Las Condes 2012; Vol. 23:173-179.
90. Greenway FL, Dunayevich E, Tollefson G, Erickson J, Gutta-dauria M, Fujioka K, Cowley MA; NB-201 Study Group. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 2009 Dec; 94(12):4898-906.
91. Halseth A, Shan K, Walsh B, Gilder K, Fujioka K. Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. Obesity (Silver Spring) 2017 Feb; 25(2):338-345.
92. Nuffer W, Trujillo JM, Megyeri J. A. comparison of new phar-macological agents for the treatment of obesity. Pub Med. Ann Pharmacother 2016 May; 50(5):376-88.
93. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of pharma-cological treatments for obesity with weight loss and adver-se events: a systematic review and meta-analysis. Pub Med. JAMA 2016 Jun 14; 315(22):2424-34.
94. Saunders KH, Umashanker D, Igel LI, Kumar RB, Aronne LJ. Obesity pharmacotherapy. Pub Med. Med Clin North Am 2018 Jan; 102(1):135-148.
95. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, dou-ble-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376:595-605.
96. Astrup A. Is cardiometabolic risk improved by weight-loss drugs? Lancet 2010; 376:567-568.
97. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, Kim D, Dunayevich E. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013 May; 21(5):935-43.
98. Khazaal Y, Zullino DF. Topiramate-induced weight loss is pos-sibly due to the blockade of conditioned and automatic pro-cesses. Eur J Clin Pharmacol 2007; 63:891-892.
99. McElroy SL, Arnold ML, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trail. Am J Psychiatr 2003; 160:255-261.
100. Khazaal Y, Zullino DF. Topiramate in the treatment of com-pulsive sexual behaviour: case report. BMC Psychiatry 2006; 6:22
101. Turenius CI, Htut MM, Prodon DA, et al. GABA (A) receptors in the lateral hypothalamus as mediators of satiety and body weight regulation. Brain Res 2009; 1262:16-24.
102. Erondu N, Gantz I, Musser B, et al. Neuropeptide Y5 recep-tor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006; 4:275-282.
103. Erondu N, Wadden T, Grantz I, et al. Effect of NPY5R an-tagonism MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity 2007; 15:895-905.
104. Husum H, Van Kammen D, Terneer E, et al. Topiramate normalizes hippocampal NPY-LI in flinders sensitive line de-pressed rats and upregulates NPY, galanin and CRH-LI in the hyppothalamus: implications for mood-stabilizing and weight loss-induced effects. Neuropsychopharmacology 2003; 28:1292-1299.
105. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-re-lease phentermine/topiramate in obese and overweight adults(SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95:297-308.
106. Hernández-Bastida A. Fentermina y topiramato contra fen-termina más placebo en pacientes con sobrepeso u obesidad clase I o II. Med Int Méx 2015; 31:125-13.
107. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combina-tion on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-con-trolled, phase 3 trial. Lancet 2011; 377: 1341-52.
108. Cosentino G, Conrad A, Uwaifo G. Phentermine and topira-mate for the management of obesity: a review. 2013. Drug Design Developement and Therapy 2013; Vol 7:267-278
109. Instituto Global Mc Kinsey. Disponible en: www.mckinsey.consights/economic_studies/how the word_ could_beMer_fight_obesity.
110. The Look AHEAD Research Group. The Look AHEAD Study: a description of the lifestyle intervention and the evidence supporting It. Obesity (Silver Spring) 2006 May; 14(5): 737-752.




REVIEW OF MOST WORLWIDE USED DRUGS FOR OBESITY

SUMMARY

Obesity is a multifactorial disease which contribute the occurrence of associated diseases (type 2 diabetes, hypertension, dyslipemia, cardiovascular diseases, some types of cancer) leading to a defcient quality of life and greater overall mortality. Obesity and its complications is one of the three main factors, together with smoking and alcoholism, which generate great economic impact. In Argentina, drugs for the treatment of obesity have been used for a long time by many physicians, who often do not have an adequate training in the prescription of these drugs, creating reckless, abusive, and risky use. There is a Guide to Clinical Practice in Obesity in the Argentine Republic, developed by the Ministry of Health. The Working Group on Drugs and Nutrition of the Argentine Nutrition Society (SAN) conducted a review of the main drugs and combinations existing around the world, so that health professionals have a scientifc reference at the time of the careful selection of them.

Key words: obesity; drugs; therapeutics.



DESCARGAR TEXTO COMPLETO EN PDF